Method for preparing conjugate

By developing 6-phosphate glucose dehydrogenase mutants and hapten conjugates for use in glycocholic acid detection kits, the contamination, cumbersome and high cost of existing glycocholic acid detection methods have been solved, and the rapid and simple The test is suitable for clinical diagnosis.

CN115808398BActive Publication Date: 2024-11-12BEIJING STRONG BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211153004.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-21
Filing Date
2019-12-27
Publication Date
2024-11-12
Estimated Expiration
2039-12-27

AI Technical Summary

Technical Problem

The existing glycocholic acid detection methods have problems such as radiocontamination, cumbersome operation, long time and high cost, and are difficult to apply to clinical testing and diagnosis.

Method used

A mutant of 6-phosphate glucose dehydrogenase was developed to form a conjugate by coupling with a hapten, and used to prepare a glycocholic acid detection kit, and the detection was performed using enzyme-linked immunization method, which improved the sensitivity and efficiency of the detection.

Benefits of technology

It realizes fast, simple and low-cost glycocholic acid detection, improves the repeatability, linearity and specificity of the detection, reduces the antibody inhibition rate, and is suitable for clinical diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115808398B_ABST
    Figure CN115808398B_ABST
Patent Text Reader

Abstract

The present application relates to a method for preparing a conjugate. Specifically, a method for preparing a conjugate is provided, comprising the steps of: 1) providing a 6-phosphate glucose dehydrogenase mutant; 2) providing a hapten; 3) coupling the 6-phosphate glucose dehydrogenase mutant and the hapten at a molar ratio of 1:1. The 6-phosphate glucose dehydrogenase mutant of the present application comprises a mutation or a combination thereof selected from the following compared to the wild-type 6-phosphate glucose dehydrogenase: D306C, D375C, G426C. The detection kit prepared using the conjugate of the present application has strong specificity, high sensitivity, convenient operation, short detection time, accurate quantification, and is suitable for high-throughput detection.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the priority of patent application 201910017764.4 filed on January 9, 2019 and patent application 201910423122.4 filed on May 21, 2019. This application is a divisional application of patent application 2019113721472 "6-Phosphate Glucose Dehydrogenase Mutant and Its Use in Preparing Detection Reagents" filed on December 27, 2019. Technical Field

[0002] The present application relates to the field of biological detection, and in particular to an enzyme 6-phosphate glucose dehydrogenase (G6PDH for short) with multiple mutations and its application in a detection kit. Background Art

[0003] Haptens are small molecules (molecular weight less than 4000Da) that cannot induce immune response alone, that is, they are not immunogenic. However, when they are cross-linked or combined with macromolecular proteins or non-antigenic carriers such as polylysine, they can become immunogenic and induce immune response. These small molecules can combine with response effect products and have antigenicity. They only have immunoreactivity but no immunogenicity, and are also called incomplete antigens.

[0004] Haptens are antigens that can combine with corresponding antibodies to produce antigen-antibody reactions, but cannot stimulate the human or animal body to produce antibodies alone. They are only immunoreactive but not immunogenic, and are also called incomplete antigens. Most polysaccharides, lipids, hormones, and small molecule drugs are haptens. If a hapten is combined with a certain protein molecule (carrier) by chemical methods, it will acquire new immunogenicity and can stimulate animals to produce corresponding antibodies. Once a hapten is combined with a protein, it forms an antigen cluster of the protein. Some substances with chemically active groups that are smaller in molecular weight than general haptens but have specific structures (such as penicillin, sulfonamides, etc.) are called simple haptens.

[0005] Small molecule antigens or half-antibodies lack more than two sites for sandwich method, so they cannot be determined by double antibody sandwich method, and competition mode is often used. The principle is that the antigen in the specimen and a certain amount of enzyme-labeled antigen compete with the solid phase antibody for binding. The more antigen content in the specimen, the less enzyme-labeled antigen is bound to the solid phase, and the lighter the color is. This method is often used for ELISA determination of small molecule hormones, drugs, etc.

[0006] Cholyglycin (CG), as a specific example of a hapten, is a conjugated bile acid formed by the combination of bile acid and glycine. It is one of the main components of bile acid. Cholesterol undergoes a series of complex enzyme-catalyzed reactions in liver cells to form primary bile acids, including cholic acid (CA) and chenodeoxycholic acid (CDCA). There are three hydroxyl groups (C3, C7, and C12) on the steroid nucleus of bile acid. The hydroxyl group at the end of the side chain is combined with glycine by a peptide bond to form cholic acid ( Figure 1 ).

[0007] Glycocholic acid is synthesized by liver cells, discharged into the gallbladder through the bile ducts and bile ducts, and enters the duodenum along with bile to help digest and absorb fat in food. 95% of bile acid is reabsorbed in the ileum and colon, and returns to the liver through the portal vein, where it is taken up and reused by liver cells. The reabsorbed glycocholic acid enters the hepato-enterocirculation again. Through this mechanism, the body can make full use of glycocholic acid.

[0008] Under normal circumstances, the content of bile acid in peripheral blood is very low. Whether fasting or after a meal, the content of glycocholic acid in the peripheral blood of normal people is at a very low level. When human liver cells are damaged or bile is stagnant, it will cause glycocholic acid metabolism and circulation disorders, reduce the ability of liver cells to absorb glycocholic acid, and lead to increased glycocholic acid content in the blood. The level of glycocholic acid is related to the severity of liver cell damage and bile acid metabolism disorders.

[0009] Determination of serum glycocholic acid content is one of the sensitive indicators for evaluating liver cell function and hepatobiliary material circulation function. Compared with conventional liver function tests such as ALT, AST, total bilirubin (TBIL), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), serum albumin (ALB), glycocholic acid determination is more sensitive. Therefore, in liver function tests such as chronic hepatitis, acute hepatitis, cirrhosis, liver cancer, obstructive liver disease, enterohepatic circulation disorders, bile duct and gallbladder excretion dysfunction, glycocholic acid can be used as a better detection indicator.

[0010] Currently known methods for detecting glycocholic acid mainly include: radioimmunoassay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, high performance liquid chromatography, gas-liquid chromatography, gas chromatography and mass spectrometry. However, these detection methods all have many defects, such as radioimmunoassay isotopes have many disadvantages such as radioactive pollution, short validity period, inconvenient operation, and enzyme-linked immunosorbent assay is more cumbersome and time-consuming, and is not suitable for clinical use. Although chemiluminescence has better sensitivity, it requires supporting special equipment, and the high cost of use is not conducive to promotion. In the clinical detection and diagnosis process, homogeneous enzyme immunoassay (EMIT) and latex enhanced immunoturbidimetry are mainly used for detection.

[0011] The principle of homogeneous enzyme immunoassay: In a liquid homogeneous reaction system, the enzyme-labeled antigen (such as G6PDH-CG) competes with the unlabeled antigen (CG) for binding with the quantitative antibody (CG antibody). The more the antibody binds to the unlabeled antigen, the more activity the enzyme-labeled antigen releases, and the more NADH is generated by the enzyme-catalyzed substrate NAD+. By detecting the absorbance change of NADH at a wavelength of 340nm, the CG content in the liquid can be inferred. Summary of the invention

[0012] In view of the needs in the art, the present application provides a novel 6-phosphate glucose dehydrogenase mutant and its use in preparing a glycocholic acid detection kit.

[0013] According to some embodiments, a 6-phosphate glucose dehydrogenase mutant is provided. Different from the mutant of 6-phosphate glucose dehydrogenase in the published patent US006090567A (Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases), the 6-phosphate glucose dehydrogenase mutant of the present application comprises mutations selected from the following: D306C, G426C, D375C.

[0014] According to some embodiments, a 6-phosphate glucose dehydrogenase mutant is provided, wherein the 6-phosphate glucose dehydrogenase mutant is selected from the following sequences: SEQ ID No.2, SEQ ID No.3, SEQ ID No.4.

[0015] According to some embodiments, a polynucleotide is provided, which encodes the 6-phosphate glucose dehydrogenase mutant of the present application.

[0016] According to some embodiments, an expression vector is provided, which comprises the polynucleotide of the present application.

[0017] According to some embodiments, a host cell is provided, which comprises the expression vector of the present application. The host cell can be a prokaryotic cell (such as bacteria) or a eukaryotic cell (such as yeast).

[0018] According to some embodiments, a conjugate is provided, which is formed by coupling the 6-phosphogluconate dehydrogenase mutant of the present application with a hapten at a molar ratio of 1:n.

[0019] In some embodiments, n is 1 to 50, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50.

[0020] In some specific embodiments, the 6-phosphate glucose dehydrogenase mutant of the present application is directional coupled with the hapten at a molar ratio of preferably 1:1.

[0021] In some specific embodiments, the molecular weight of the hapten is 100Da to 4000Da, for example: 100, 150, 200, 250, 300, 350, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 520, 550, 570, 600, 620, 650, 700, 750, 800, 850, 900, 950, 1000Da, 1000Da, 1000Da, 1000Da, 1000Da, 1000Da, 1000Da, 1000Da, 1000Da 000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000.

[0022] According to the present application, the skilled person will understand that "hapten" also includes its derivative form. In order to facilitate coupling with 6-phosphate glucose dehydrogenase, those haptens (such as CG) that do not have a coupling group (for example, a group that reacts with a sulfhydryl group) can be modified to have a linker so as to covalently bind to the sulfhydryl group. Therefore, in the present application, a hapten derivative refers to a hapten that has been modified to have a sulfhydryl reactive group.

[0023] The hapten is selected from: small molecule drugs (such as antibiotics, psychotropic drugs), hormones, metabolites, sugars, lipids, amino acids, short peptides (molecular weight less than 4000 kDa, or amino acid length not exceeding 50 residues).

[0024] Haptens include, but are not limited to, vitamin D, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, folic acid, cardiac glycosides, phenolic acid, rapamycin, cyclosporine A, amiodarone, methotrexate, tacrolimus, serum amino acids, bile acids, glycocholic acid, phenylalanine, ethanol, urinary nicotinic metabolite cotinine, urinary morphine, urinary monohydroxyphenol derivatives, neuropeptide tyrosine, plasma galanin, polyamines, histamine, thyroid stimulating hormone, prolactin, placental lactogen, growth hormone, follicle stimulating hormone, luteinizing hormone, adrenocorticotropic hormone, antidiuretic hormone, calcitonin, procalcitonin, parathyroid hormone, thyroxine, triiodothyronine, anti-triiodothyronine, free thyroxine, free triiodothyronine , cortisol, urinary 17-hydroxycorticosteroids, urinary 17-ketosteroids, dehydroepiandrosterone and sulfate, aldosterone, urinary vanilloid mandelic acid, plasma renin, angiotensin, erythropoietin, testosterone, dihydrotestosterone, androstenedione, 17α-hydroxyprogesterone, estrone, estriol, estradiol, progesterone, human chorionic gonadotropin, insulin, proinsulin, C-peptide, gastrin, plasma prostaglandins, plasma 6-ketoprostaglandin F1α, prostacyclin, epinephrine, catecholamines, norepinephrine, cholecystokinin, natriuretic peptide, cyclic adenosine monophosphate, cyclic guanosine monophosphate, vasoactive peptide, somatostatin, secretin, substance P, neurotensin, thromboxane A2, thromboxane B2, serotonin, neuropeptide Y, osteocalcin.

[0025] In a specific embodiment, the hapten is glycocholic acid or a derivative thereof. Although glycocholic acid is used as a specific example, the skilled person will appreciate that the technical effect of the present application is independent of the specific type of hapten, and is applicable to any hapten that can be immunologically detected by competitive methods.

[0026] In a specific embodiment, the hapten is a glycocholic acid derivative with a sulfhydryl reactive group, such as imide, bromoacetyl, vinyl sulfone or aziridine. In a specific embodiment, the hapten is a glycocholic acid derivative, as shown in Formula I:

[0027]

[0028] According to some embodiments, a reagent is provided, which comprises the conjugate of the present application.

[0029] According to some embodiments, provided is the use of the 6-phosphate glucose dehydrogenase mutant of the present application in preparing a detection reagent.

[0030] According to some embodiments, there is provided use of the conjugate of the present application in preparing a detection reagent.

[0031] In a specific embodiment, the detection reagent is selected from: enzyme-linked immunosorbent assay detection reagent, chemiluminescent immunoassay detection reagent, homogeneous enzyme immunoassay detection reagent, latex-enhanced immunoturbidimetric detection reagent.

[0032] In a specific embodiment, the detection reagent is preferably a reagent based on competition detection.

[0033] According to some embodiments, a glycocholic acid detection kit is provided, comprising:

[0034] - a first reagent, wherein the first reagent comprises a substrate and a glycocholic acid antibody; the substrate is a substrate of 6-phosphate glucose dehydrogenase;

[0035] - a second reagent, which comprises the conjugate of the present application;

[0036] -optionally, a calibrator comprising 10 mM to 500 mM buffer, 0 mg / L to 40 mg / L glycocholic acid; and

[0037] -Optionally, a quality control product, the quality control product comprising 10 mM to 500 mM buffer, 0 mg / L to 40 mg / L glycocholic acid.

[0038] According to one embodiment, a glycocholic acid detection kit is provided, comprising:

[0039] The first reagent comprises:

[0040] 10mM to 500mM buffer,

[0041] 5mM to 25mM substrate,

[0042] 0.1mg / L to 1mg / L of glycocholic acid antibody,

[0043] 10mM to 300mM NaCl,

[0044] 0.1g / L to 5g / L stabilizer,

[0045] 0.1g / L to 5g / L surfactant,

[0046] 0.1g / L to 5g / L preservatives;

[0047] A second reagent comprising:

[0048] 10mM to 500mM buffer,

[0049] The conjugate according to claim 5,

[0050] 0.1g / L to 5g / L stabilizer,

[0051] 0.1g / L to 5g / L surfactant,

[0052] 0.1g / L to 5g / L preservatives.

[0053] In some embodiments, the buffer is selected from one or a combination of the following: tromethamine buffer, phosphate buffer, Tris-HCl buffer, citric acid-sodium citrate buffer, barbital buffer, glycine buffer, borate buffer, tris(hydroxymethyl)methane buffer; preferably, phosphate buffer; the concentration of the buffer is 10 mmol / L to 500 mmol / L, preferably 100 mM; the pH of the buffer is 6.5 to 7.5, preferably 7.2 or 7.0.

[0054] In some embodiments, the stabilizer is selected from one or a combination of the following: bovine serum albumin, trehalose, glycerol, sucrose, mannitol, glycine, arginine, polyethylene glycol 6000, polyethylene glycol 8000; preferably bovine serum albumin.

[0055] In some embodiments, the surfactant is selected from one or a combination of the following: Brij35, Triton X-100, Triton X-405, Tween20, Tween30, Tween80, coconut oil fatty acid diethanolamide, AEO7, preferably Tween20.

[0056] In some embodiments, the preservative is selected from one or a combination of the following: azide, MIT, PC-300, thimerosal; the azide is selected from sodium azide, lithium azide.

[0057] In some embodiments, the substrate comprises: 6-phosphoglucose, β-nicotinamide adenine dinucleotide.

[0058] In some embodiments, the concentration of the buffer is 100 mM.

[0059] In some embodiments, the substrate concentration for the G6PDH enzyme-catalyzed reaction is 5 mM.

[0060] In some embodiments, the concentration of the glycocholic acid antibody is 0.1 mg / L.

[0061] In some embodiments, the concentration of NaCl is 300 mM.

[0062] In some embodiments, the concentration of the stabilizer is 0.5 g / L.

[0063] In some embodiments, the concentration of the surfactant is 0.1 g / L.

[0064] In some embodiments, the concentration of the preservative is 1 g / L.

[0065] According to some embodiments, a method for preparing a conjugate is provided, comprising the steps of:

[0066] 1) providing a hapten or a derivative thereof according to the present application, in particular providing a hapten or a derivative thereof according to the present application in an aprotic solvent (for example but not limited to acetonitrile, dimethylformamide, dimethyl sulfoxide);

[0067] 2) providing the 6-phosphate glucose dehydrogenase mutant of the present application, preferably providing the 6-phosphate glucose dehydrogenase mutant in a buffer (which provides a reaction environment, such as but not limited to PBS, Tris, TAPS, TAPSO, and the buffer has a pH of 6.0 to 8.0);

[0068] 3) contacting the 6-phosphate glucose dehydrogenase mutant and the hapten or its derivative at a molar ratio of 1:n for 1 hour to 4 hours (preferably 2 hours to 3 hours) at 18° C. to 28° C. to allow the hapten or its derivative and the 6-phosphate glucose dehydrogenase mutant to couple, thereby obtaining the conjugate;

[0069] 4) If necessary, the conjugate may be purified, for example, by desalting.

[0070] In some embodiments, n is 1 to 50, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50.

[0071] In some specific embodiments, steps 1) and 2) can be interchanged or performed in parallel.

[0072] In some specific embodiments, prior to conjugation, the 6-phosphate glucose dehydrogenase contains a free sulfhydryl group, thereby allowing a 1:1 directed reaction with a hapten or a derivative thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 .Structure diagram of glycocholic acid.

[0074] Figure 2 .Structure diagram of glycocholic acid derivatives.

[0075] Figure 3A.G6PDH (wild type) amino acid sequence (SEQ ID No. 1); derived from Leuconostoc pseudomesenteroides.

[0076] Figure 3B .G6PDH(D306C) amino acid sequence (SEQ ID No.2).

[0077] Figure 3C .G6PDH(D375C) amino acid sequence (SEQ ID No.3).

[0078] Figure 3D .G6PDH (G426C) amino acid sequence (SEQ ID No. 4). DETAILED DESCRIPTION

[0079] Example

[0080] Example 1. Synthesis of glycocholic acid derivatives

[0081] Add glycocholic acid (1.0 eq), maleimidoethylamine (1.0 g, 1.0 eq), and triethylamine (3.0 eq) into a dry, clean 25 mL two-necked bottle;

[0082] Add dimethylformamide (5 mL) and stir until completely dissolved, add dichloroethane (1.25 eq), and stir at 25 °C for 2 h;

[0083] HPLC monitoring until the reaction is complete;

[0084] The above reaction mixture was added to water (25 mL), and ethyl acetate (20 mL × 3) was added for extraction;

[0085] The organic phases were combined, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The resulting oil was purified by column chromatography to obtain 1.04 g of a milky white powdery solid with a yield of 45%, M+: 602.72.

[0086] The purpose of this embodiment is to make CG carry a group that can bind to the enzyme. The technical effect of this application does not depend on a specific hapten derivative.

[0087] Example 2. Coupling of glycocholic acid derivatives with G6PDH molecules

[0088] According to the G6PDH-glycocholic acid conjugate of the present application, the conjugation is carried out in the following manner: the sulfhydryl reactive group (such as maleimide group) on the glycocholic acid derivative molecule is covalently bonded to the sulfhydryl group on the G6PDH molecule.

[0089] 1. Solution preparation:

[0090] Glycocholic acid derivative solution: 10 mg / ml of the glycocholic acid derivative prepared in Example 1 was dissolved in DMF;

[0091] G6PDH solution: 6.7 mg / mL G6PDH (mutant or control mutant of the present application), PB 100 mmol, NaCl 100 mmol, pH = 8.0;

[0092] Coupling solution: 100 mM PB / K, 100 mM EDTA, 150 mM NaCl, pH = 7.2;

[0093] Desalting solution: 100 mM PB / K, 100 mM EDTA, 150 mM NaCl, pH = 7.2.

[0094] 2. Coupling operation: 1.6 ml of G6PDH solution, 6 ml of coupling solution and 0.40 ml of glycocholic acid derivative solution were reacted at room temperature (20 to 25°C) for 4 hours.

[0095] 3. After the reaction system was shaken at room temperature for 4 hours, the desalting column was used for elution with the desalting solution, and the protein peak was collected. The obtained product was G6PDH-glycocholic acid conjugate.

[0096] Example 3. Preparation of the kit

[0097] The following kit for detecting glycocholic acid is prepared, comprising:

[0098] Reagent R1, comprising:

[0099] 100 mM PB buffer, pH 7.2

[0100] 15mM Glucose 6-phosphate

[0101] 15mM β-nicotinamide adenine dinucleotide

[0102] 0.1mg / L Glycocholic Acid Antibody

[0103] 200mM NaCl

[0104] 0.5g / L bovine serum albumin

[0105] 0.1g / L Tween20

[0106] 1g / L sodium azide;

[0107] Reagent R2, comprising:

[0108] 100 mM PB buffer, pH 7.2

[0109] 0.1mg / L G6PDH-CG conjugate

[0110] 0.5g / L bovine serum albumin

[0111] 0.1g / L Tween 20

[0112] 1g / L sodium azide;

[0113] Calibrator: 100 mM PB buffer, pH 7.2, and 0, 2.5, 5.0, 10, 20, 40 mg / L glycocholic acid (or add as needed);

[0114] Quality control: 100 mM PB buffer, pH 7.2, and 1.5, 8.0, 25, 35 mg / L glycocholic acid (or add as needed).

[0115] Test example

[0116] Reaction time: 10 min, of which the incubation time is 4.7 min. After adding reagent R2 and incubating for 1 min, the absorbance A1 is measured and read. After incubating for 1 min, the absorbance A2 is measured and read. Calculate ΔA = (A2-A1) / min. Calculate the content of glycocholic acid in the sample through the calibration curve: CG = sample tube absorbance * calibration substance concentration / calibration substance absorbance.

[0117] The performance of the glycocholic acid detection kit prepared in Example 3 was tested, and the main detection performances were total imprecision, repeatability, recovery, linearity, specificity, etc.

[0118] Table 1. Parameters of fully automatic biochemical analyzer

[0119] Detection model Hitachi 7180 Analysis / Time / Point 2 point rate / 10min / 20-24 points R1 / R2 / S 120:40:9 Wavelength (Secondary / Main) 405 / 340 Reaction Type Increment Calibration Type Spine type Calibration Points 6 Calibrator concentration 0 / 2.50 / 5.00 / 10.00 / 20.00 / 40.00

[0120] Test Example 1. Calibration of absorbance of glycocholic acid test kit

[0121] Table 2. Calibrated absorbance of glycocholic acid detection kit

[0122]

[0123] Test Example 2. Total Imprecision of Glycocholic Acid Test Kit

[0124] Table 3. Total imprecision

[0125]

[0126] Test Example 3. Repeatability of Glycocholic Acid Test Kit

[0127] Table 4. Repeatability

[0128]

[0129] Detection Example 4. Recovery of Glycocholic Acid Detection Kit

[0130] Table 5. Recycling

[0131]

[0132]

[0133] Test Example 5. Linearity of Glycocholic Acid Test Kit

[0134] Table 6. Linearity

[0135]

[0136]

[0137] Detection Example 6. Glycocholic Acid Detection Kit Anti-Specificity

[0138] Table 7. Specificity

[0139] Interfering substances (40 μg / ml) Reagent of this application (D306C) Control reagent (A45C mutant) Glycodeoxycholic acid 18.61% 30.20% Glycochenodeoxycholic acid 1.63% 37.91% Chenodeoxycholic acid 0.61% 16.28% Ursodeoxycholic acid -0.42% 6.55% Sodium Cholate 61.21% 61.90% Sodium deoxycholate 4.22% 11.74%

[0140] The reagent of the present application has little or no cross-reaction with the structural analogs of glycocholic acid.

[0141] Test Example 7. Antibody Inhibition Rate

[0142] 1. Principle of antibody inhibition rate detection

[0143] When the antibody binds to the G6PDH-CG conjugate, the G6PDH enzyme activity is affected due to steric hindrance, thereby reducing its efficiency in catalyzing the conversion of NAD to NADH. By detecting the change in the amount of NADH, the difference between the experimental group with and without the antibody is compared. This difference is reflected in the antibody's inhibitory ability on G6PDH.

[0144] 2. Reaction system:

[0145] Table 8. Preparation of antibody inhibition rate detection reagents

[0146]

[0147] Table 9. Antibody inhibition rate test parameters

[0148] Detection model Hitachi 7180 Analysis / Time / Point 2 point rate / 10min / 20-24 points R1 / S 120:20 Wavelength (Secondary / Main) 405 / 340 Reaction Type Increment

[0149] 3. Results:

[0150] By comparing the absorbance values ​​of the G6PDH-CG conjugate when the antibody is added and when the antibody is not added, the inhibition of the antibody on G6PDH can be obtained.

[0151] Antibody inhibition rate = absorbance change value of G6PDH-CG in the presence of antibody / absorbance change value of G6PDH-CG in the absence of antibody.

[0152] Compared with the published mutation sites, the mutants of the present application have significantly improved antibody inhibition rate, reaching more than 30%, and up to 50%, while the inhibition rate of the previously commonly used mutation sites (such as A45C, K55C) is only about 20% or even lower.

[0153] Table 10. Antibody inhibition rate of different G6PDH mutants

[0154]

[0155]

[0156] Although not limited to a specific theory, it can be partially explained as follows: compared with the G6PDH mutants in the prior art, the mutation site (i.e., the site where the free thiol group is introduced) in the enzyme mutants (D306C, D375C, G426C) of the present application is the location where the coupling occurs with the hapten (such as hormones, small molecule drugs, etc.). When the hapten binds to the hapten-specific antibody at this position, the steric hindrance formed has the greatest impact on the activity of the G6PDH enzyme. At the same time, after the introduction of the mutation, it cannot substantially affect the spatial folding of the molecule. Therefore, the location of this mutation site is very important, and it is necessary to take into account the activity of the G6PDH enzyme, the spatial folding of the coupled molecule, and the full exposure of the hapten epitope.

[0157] Since the enzyme mutant has a significant improvement in antibody inhibition rate, it can have a significant advantage in calibrating absorbance. After the enzyme mutant is coupled with the hapten and formulated into a kit, the reagent has a significant performance improvement in repeatability, total imprecision, linearity, specificity and other performances due to the improvement of the calibration curve.

Claims

1. A method for preparing a conjugate, comprising the steps of: 1) providing a 6-phosphate glucose dehydrogenase mutant; 2) provide hapten; 3) the 6-phosphate glucose dehydrogenase mutant is coupled to the hapten at a molar ratio of 1:1; The hapten is a glycocholic acid derivative; Step 1) and step 2) can be performed in parallel or in an interchangeable order; Compared to the wild-type 6-phosphate glucose dehydrogenase of Leuconostoc pseudomesenteroides, the 6-phosphate glucose dehydrogenase mutant comprises any one of the following mutations: D306C, D375C, G426C; The 6-phosphoglucose dehydrogenase mutant is selected from any one of the following sequences: SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4; The glycocholic acid derivative is shown in Formula I: